Neurogene Inc (NGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,209 | -2,208 | -31,585 | -26,698 | -11,705 |
| Depreciation Amortization | 134 | 62 | 289 | N/A | N/A |
| Accounts receivable | -246 | -403 | 1,041 | 720 | -174 |
| Other Working Capital | -4,038 | -1,700 | -5,431 | 407 | 2,150 |
| Other Operating Activity | 2,133 | 1,493 | 4,109 | 3,769 | 3,321 |
| Operating Cash Flow | $-4,226 | $-2,756 | $-31,577 | $-21,802 | $-6,408 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -49 | -49 | -69 |
| Sale Of Investment | N/A | N/A | 56,000 | 56,000 | 53,000 |
| Investing Cash Flow | $N/A | $N/A | $55,951 | $55,951 | $52,931 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -4 | -2 | -32 | -30 | -8 |
| Common Stock Issued | N/A | N/A | 602 | 602 | 602 |
| Financing Cash Flow | $-4 | $-2 | $570 | $572 | $594 |
| Exchange Rate Effect | 2 | -1 | -48 | -22 | -19 |
| Beginning Cash Position | 76,928 | 76,928 | 52,032 | 52,032 | 52,032 |
| End Cash Position | 72,700 | 74,169 | 76,928 | 86,731 | 99,130 |
| Net Cash Flow | $-4,228 | $-2,759 | $24,896 | $34,699 | $47,098 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,226 | -2,756 | -31,577 | -21,802 | -6,408 |
| Capital Expenditure | N/A | N/A | -49 | -49 | -69 |
| Free Cash Flow | -4,226 | -2,756 | -31,626 | -21,851 | -6,477 |